Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Completed · Phase 3

Conditions studied: Actinic Keratoses

In brief

The aim of this study is to test the safety. tolerability and efficacy of field-directed photodynamic therapy (PDT) with 10% aminolevulinic acid gel (Ameluz®, BF-200 ALA) in combination with one of the narrow spectrum red light RhodoLED lamps in comparison to vehicle treatment for actinic keratosis (AK) on the extremities and neck/trunk.

Key facts

Study ID

NCT05662202

Run by

Biofrontera Inc.

People needed

172

Starts

2022-12-12

Expected to finish

2026-07-01

Last updated by the study team

2026-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Willingness and ability of subjects to provide informed consent and sign the Health Insurance Portability and Accountability Act (HIPAA) form. A study-specific informed consent and HIPAA form must be obtained in writing prior to starting any study procedures.
• 4 - 15 mild to moderate clinically confirmed AK lesions according to Olsen either on the extremities or on the neck/trunk with a diameter of ≥ 4 mm that must be present in the treatment field (defined as AK target lesions). In addition, non-target AK lesions may be present in the treatment field, including up to two severe AK lesions ≥ 4 mm. For each severe AK lesion (≥ 4 mm), a biopsy must be taken for confirmation of diagnosis. The treatment field (continuous or in several patches) totaling approx. either 80 cm², 160 cm² or 240 cm2 must be within one effective illumination area of the BF-RhodoLED® XL but may require up to three illuminations with the BF-RhodoLED®. All AK target lesions and, if applicable, severe AK lesions ≥ 4 mm located in the treatment field should be clearly distinguishable, without restrictions on the distance between lesions, and should have a minimal distance of 1 cm to the border of the treatment field.
• All sexes, ≥ 18 years of age.
• Willingness to undergo a 2 mm punch biopsy for each (up to two) severe AK lesion ≥ 4 mm, if applicable, at the screening visit.
• Willingness and ability to comply with study procedures, particularly willingness to receive up to 2 PDTs within approximately 12 weeks.
• Subjects with good general health or with clinically stable medical conditions will be permitted to be included in the study.
• Willingness to stop the use of moisturizers and any other non-medical topical treatments within the treatment field at least 24 h prior to the next clinical visit.
• Acceptance to abstain from extensive sunbathing and the use of a solarium or tanning beds during the treatment phase.
• For female subjects with reproductive potential: Negative serum pregnancy test.
• For female subjects with reproductive potential: Effective contraception at screening visit and throughout the treatment phase of the study (until Visit 4 or Visit 6).

You may not qualify if…

• Any known history of hypersensitivity to ALA, porphyrins, or excipients of BF-200 ALA.
• History of soy or peanut allergy.
• Sunburn or other possible confounding skin conditions (e.g., wounds, irritations, bleeding, or skin infections) inside or in close proximity (< 2 cm distance) to the treatment field.
• Clinically significant (cs) medical conditions making implementation of the protocol or interpretation of the study results difficult or impairing subject's safety such as:
• Presence of photodermatoses or porphyria
• Metastatic tumor or tumor with high probability of metastasis
• Infiltrating skin neoplasia (suspected or known)
• Unstable cardiovascular disease (New York Heart Association class III, IV)
• Unstable hematologic (including myelodysplastic syndrome), hepatic, renal, neurologic, or endocrine condition
• Unstable collagen-vascular condition
• Unstable gastrointestinal condition
• Immunosuppressive condition
• Presence of clinically significant inherited or acquired coagulation defect
• Clinical diagnosis of atopic dermatitis, Bowen´s disease (BD), basal cell carcinoma (BCC), eczema, psoriasis, rosacea, squamous cell carcinoma (SCC), other malignant or benign tumors inside or in close proximity (< 2 cm distance) to the treatment field.
• Presence of strong artificial pigmentation (e.g., tattoos) or any other abnormality that may impact lesion assessment or light penetration in the treatment field.
• Any physical therapy such as cryotherapy, laser therapy, electrodessication, microdermabrasion, surgical removal of lesions, curettage, or treatment with chemical peels such as trichloroacetic acid inside or in close proximity (< 10 cm distance) to the treatment field within 4 weeks prior to screening.
• Any of the topical treatments defined below within the designated periods prior to screening:
• Topical treatment with ALA or ALA esters (e.g., methyl aminolevulinic acid (MAL)) inside the treatment field within 3 months.
• Topical treatment with immunomodulatory, cytostatic, or cytotoxic drugs inside or in close proximity (< 10 cm distance) to the treatment field within 3 months.
• Start of topical administration of a medication with hypericin or other drugs with phototoxic or photoallergic potential inside or in close proximity (< 10 cm distance) to the treatment field within 4 weeks. Subjects may, however, be eligible if such medication was applied for more than 4 weeks prior to screening without evidence of an actual phototoxic/photoallergic reaction.
• Any use of the systemic treatments within the designated periods prior to screening:
• Cytostatic or cytotoxic drugs within 6 months.
• Immunosuppressive therapies or ALA or ALA esters (e.g., MAL) within 12 weeks.
• Drugs known to have major organ toxicity within 8 weeks.
• Interferon or glucocorticosteroids within 6 weeks.

Where it is running

• Medical Dermatology Specialists — Phoenix, Arizona, United States
• Alliance Dermatology & Mohs Center — Phoenix, Arizona, United States
• Dermatology Practice — Greenwood Village, Colorado, United States
• Dermatology Associates PA of the Palm Beaches — Delray Beach, Florida, United States
• Gwinnett Clinical Research Center, Inc. — Snellville, Georgia, United States
• Laser and Skin Surgery Center of Indiana — Indianapolis, Indiana, United States
• The Indiana Clinical Trials Center, PC — Plainfield, Indiana, United States
• DelRicht Research — Baton Rouge, Louisiana, United States
• Skin Search of Rochester, Inc. — Rochester, New York, United States
• Rochester Dermatologic Surgery — Victor, New York, United States
• Clinical Research Center of the Carolinas — Charleston, South Carolina, United States
• DermResearch, P.A. — Austin, Texas, United States
• Austin Institute for Clinical Research — Houston, Texas, United States
• Austin Institute for Clinical Research Inc. — Pflugerville, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.